Correlation Between Medicenna Therapeutics and Cardiol Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Medicenna Therapeutics and Cardiol Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Medicenna Therapeutics and Cardiol Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Medicenna Therapeutics Corp and Cardiol Therapeutics Class, you can compare the effects of market volatilities on Medicenna Therapeutics and Cardiol Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Medicenna Therapeutics with a short position of Cardiol Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Medicenna Therapeutics and Cardiol Therapeutics.

Diversification Opportunities for Medicenna Therapeutics and Cardiol Therapeutics

0.76
  Correlation Coefficient

Poor diversification

The 3 months correlation between Medicenna and Cardiol is 0.76. Overlapping area represents the amount of risk that can be diversified away by holding Medicenna Therapeutics Corp and Cardiol Therapeutics Class in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cardiol Therapeutics and Medicenna Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Medicenna Therapeutics Corp are associated (or correlated) with Cardiol Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cardiol Therapeutics has no effect on the direction of Medicenna Therapeutics i.e., Medicenna Therapeutics and Cardiol Therapeutics go up and down completely randomly.

Pair Corralation between Medicenna Therapeutics and Cardiol Therapeutics

Assuming the 90 days trading horizon Medicenna Therapeutics Corp is expected to under-perform the Cardiol Therapeutics. In addition to that, Medicenna Therapeutics is 1.36 times more volatile than Cardiol Therapeutics Class. It trades about -0.19 of its total potential returns per unit of risk. Cardiol Therapeutics Class is currently generating about -0.11 per unit of volatility. If you would invest  189.00  in Cardiol Therapeutics Class on October 20, 2024 and sell it today you would lose (13.00) from holding Cardiol Therapeutics Class or give up 6.88% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Medicenna Therapeutics Corp  vs.  Cardiol Therapeutics Class

 Performance 
       Timeline  
Medicenna Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Medicenna Therapeutics Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Cardiol Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Cardiol Therapeutics Class has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Medicenna Therapeutics and Cardiol Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Medicenna Therapeutics and Cardiol Therapeutics

The main advantage of trading using opposite Medicenna Therapeutics and Cardiol Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Medicenna Therapeutics position performs unexpectedly, Cardiol Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardiol Therapeutics will offset losses from the drop in Cardiol Therapeutics' long position.
The idea behind Medicenna Therapeutics Corp and Cardiol Therapeutics Class pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Other Complementary Tools

Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Fundamental Analysis
View fundamental data based on most recent published financial statements